菌酸莫菲提尔加上甲甲酸与循环胺与顺序性阿扎西奥普林用于治疗塔卡亚苏动脉炎
Xiaochuan Sun1, Jing Li2, Xinwang Duan3
1Department of Internal Medicine, Peking Union Medical College Hospital, Beijing, China.
Annals of the rheumatic diseases
|August 23, 2025
概括
在治疗活跃的塔卡亚苏动脉炎 (TAK) 方面,甲 (MMF) 与甲 (MTX) 相比,甲 (CYC) 和阿扎西奥普林 (AZA) 的疗效更高. 这种组合为TAK患者提供了耐受性良好且具有成本效益的治疗选择.
科学领域:
- 关节病学
- 免疫学
- 血管医学
背景情况:
- 塔卡亚苏动脉炎 (TAK) 是一种罕见的,慢性炎症性疾病,影响大动脉.
- 目前对活性TAK的治疗策略通常涉及免疫抑制剂,但最佳治疗方案仍在研究中.
- 为了改善患者的治疗结果和治疗这种罕见的血管炎,比较不同的免疫抑制药物组合至关重要.
研究的目的:
- 评估与甲基酸盐 (MTX) 结合的mycophenolate mofetil (MMF) 与其后的阿扎西奥普林 (AZA) 在患有活跃的塔卡苏动脉炎 (TAK) 的成年人的疗效和安全性.
- 确定28周和52周的整体响应率,完全响应率和部分响应率.
- 评估两组治疗中复发和严重不良事件的发生率.
主要方法:
- 这是一项随机对照试验,涉及111名活跃TAK的成年患者.
- 患者被随机分配 (2:1) 接受口服MMF加MTX或静脉CYC,然后口服AZA.
- 所有患者都接受高剂量的口服皮质糖类药物,并逐渐减少;主要终点是52周的整体应答率.
主要成果:
- 与CYC/ AZA组 (n=37) 相比,MMF+MTX组 (n=74) 在28周 (58. 1%) 和52周 (55. 4%) 的整体应答率显著更高 (32. 4% 在两个时间点;P=0. 011和0. 022).
- 在28周和52周的MMF+MTX组中,完全和部分反应率也较高.
- 在CYC/ AZA组中,复发率相似 (MMF+MTX组为4例,CYC/ AZA组为2例),其中CYC/ AZA组有1例严重不良反应 (带发烧的中性衰退).
结论:
- 使用MMF和MTX的联合治疗对治疗活跃的塔卡亚苏动脉炎比使用CYC和AZA更有效.
- MMF加MTX具有良好的疗效概况,通常耐受性良好,并且具有成本效益.
- 这种组合代表了有效的治疗选择,支持其在临床实践中的使用.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Pulmonary Tuberculosis V
238
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
238
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202
Myocarditis III: Medical Management
15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15


